CABALETTA BIO INC's ticker is CABA and the CUSIP is 12674W109. A total of 69 filers reported holding CABALETTA BIO INC in Q1 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $472,475 | +166.4% | 31,043 | +126.0% | 0.00% | – |
| Q2 2023 | $177,332 | +944.4% | 13,736 | +569.1% | 0.00% | – |
| Q1 2023 | $16,979 | +39.3% | 2,053 | +55.8% | 0.00% | – |
| Q4 2022 | $12,192 | +509.6% | 1,318 | -65.4% | 0.00% | – |
| Q3 2022 | $2,000 | -50.0% | 3,814 | +0.8% | 0.00% | – |
| Q2 2022 | $4,000 | -42.9% | 3,782 | +3.2% | 0.00% | – |
| Q1 2022 | $7,000 | -87.9% | 3,663 | -76.3% | 0.00% | – |
| Q4 2021 | $58,000 | -79.3% | 15,430 | -32.9% | 0.00% | – |
| Q3 2021 | $280,000 | +42.1% | 22,984 | +0.5% | 0.00% | – |
| Q2 2021 | $197,000 | -29.6% | 22,860 | -9.6% | 0.00% | – |
| Q1 2021 | $280,000 | -56.0% | 25,291 | -50.5% | 0.00% | – |
| Q4 2020 | $637,000 | +66.8% | 51,084 | +45.1% | 0.00% | – |
| Q3 2020 | $382,000 | -59.4% | 35,210 | -58.3% | 0.00% | – |
| Q2 2020 | $941,000 | +1494.9% | 84,468 | +941.9% | 0.00% | – |
| Q1 2020 | $59,000 | +742.9% | 8,107 | +1426.7% | 0.00% | – |
| Q4 2019 | $7,000 | – | 531 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 2,106,000 | $32,053,320 | 21.20% |
| COMMODORE CAPITAL LP | 2,525,753 | $38,441,961 | 4.49% |
| Bain Capital Life Sciences Investors, LLC | 2,000,000 | $30,440,000 | 3.40% |
| VR Adviser, LLC | 1,973,253 | $30,032,911 | 3.16% |
| Cormorant Asset Management, LP | 2,879,424 | $43,824,833 | 2.56% |
| Velan Capital Investment Management LP | 150,000 | $2,283,000 | 1.84% |
| Redmile Group, LLC | 1,774,252 | $27,004,115 | 1.28% |
| TCG Crossover Management, LLC | 486,795 | $7,409,020 | 1.09% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,340,118 | $35,616,596 | 0.78% |
| Integral Health Asset Management, LLC | 330,000 | $5,022,600 | 0.70% |